 This study will enroll 390 participants. Participants will be randomized 1:1 ratio to FMT or placebo, stratified by number of prior recurrent CDI episodes 1 versus 1. They will be assessed for symptoms of CDI, other study outcomes and any treatment-related adverse events at 2, 14, 28, 42, and 56 days, and month 3, 4, 5 and 6 after administration of the study treatment. 